Preclinical models used for immunogenicity prediction of therapeutic proteins

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1719-1728

  Brinks, Vera ^a   Weinbuch, Daniel ^b   Baker, Matthew ^c   Dean, Yann ^d   Stas, Philippe ^e   Kostense, Stefan ^f   Rup, Bonita ^g   Jiskoot, Wim ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Antitope Ltd   (United Kingdom)

^d Eclosion   (Switzerland)

^e BLA Consult Bvba ^*  (Belgium)

^f CRUCELL HOLLAND BV   (Netherlands)

^g PFIZER INC   (United States)

Author keywords

immunogenicity; predictive models; therapeutic proteins

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DRUG ANTIBODY; EPITOPE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ANTIBODY;

ACCURACY; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; COMPUTER MODEL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; PROTEINS;

EID: 84878849764     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1062-z     Document Type: Review

References (73)

1. Clarke JB. Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol. 2010;196:453-74.
2. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817-21.
3. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P. Immunogenicity of interferon beta: differences among products. J Neurol. 2004;251 Suppl 2:II15-24.
4. De Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009;68(11):1787-8.
5. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18(3):473-80. (Pubitemid 40425360)
6. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754-62.
7. Yang J, Joo KW, Kim YS, Ahn C, Han JS, Kim S, et al. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J Nephrol. 2005;18(1):102-5. (Pubitemid 40723760)
8. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28(10):2379-85.
9. Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs. 2010;24(1):1-8.
10. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010;137(1):5-14.
11. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev. 2008;14:191-202. (Pubitemid 351903454)
12. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:vi3-9.
13. Stas P, Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs. 2009;12(3):169-73.
14. De Groot AS, Knopp PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel). 2005;122:171-94. (Pubitemid 43002219)
15. Perry LCA, Jones TD, Baker MP. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D. 2008;9(6):385-96.
16. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314-22.
17. Bian H, Hammer J. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods. 2004;34(4):468-75. (Pubitemid 39469054)
18. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz RM, Deocampo G. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retrovir. 1997;13(7):529-31. (Pubitemid 27190560)
19. Dönnes P, Kohlbacher O. SVMHC: a server for prediction of MHC-binding peptides. Nucleic Acids Res. 2006;34(Web Server issue):W194-7.
20. Van Walle I, Gansemans Y, Parren PWHI, Stas P, Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther. 2007;7(3):405-18. (Pubitemid 46383483)
21. Lata S, Bhasin M, Raghava GPS. Application of machine learning techniques in predicting MHC binders. Methods Mol Biol. 2007;409:201-15.
22. Davies MN, Sansom CE, Beazley C, Moss DS. A novel predictive technique for the MHC class II peptide-binding interaction. Mol Med. 2003;9(9-12):220-5. (Pubitemid 38858176)
23. Desmet J, Meersseman G, Boutonnet N, Pletinckx J, De Clercq K, Debulpaep M, et al. Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation. Proteins. 2005;58(1):53-69. (Pubitemid 39665616)
24. Lundegaard C, Hoof I, Lund O, Nielsen M. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res. 2010;6 Suppl 2:S3.
25. Fonseca SG, Coutinho-Silva A, Fonseca LAM, Segurado AC, Moraes SL, Rodrigues H, et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS. 2006;20(18):2263-73. (Pubitemid 44789528)
26. Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, de Jesus AR, Carvalho EM, et al. Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection. Clin Exp Immunol. 2005;142(3):539-47. (Pubitemid 41719851)
27. Veeraraghavan S, Renzoni EA, Jeal H, Jones M, Hammer J, Wells AU, et al. Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. Ann Rheum Dis. 2004;63(8):982-7. (Pubitemid 38961925)
28. Iwai LK, Yoshida M, Sidney J, Shikanai-Yasuda MA, Goldberg AC, Juliano MA, et al. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol Med. 2003;9(9-12):209-19. (Pubitemid 38858175)
29. Kapoerchan VV, Wiesner M, Hillaert U, Drijfhout JW, Overhand M, Alard P, et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol Immunol. 2010;47(5):1091-7.
30. Anthony DD, Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods. 2003;29(3):260-9. (Pubitemid 36513442)
31. Mashishi T, Gray CM. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med. 2002;40(9):903-10. (Pubitemid 35277416)
32. James EA, LaFond R, Durinovic-Bello I, Kwok W. Visualizing antigen specific CD4+ T cells using MHC class II tetramers. J Vis Exp. 2009;(25).
33. Hu G-L, Okita DK, Conti-Fine BM. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. J Thromb Haemost. 2004;2(11):1908-17. (Pubitemid 40192743)
34. Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005;3(5):991-1000. (Pubitemid 41632831)
35. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol. 1995;7(3):349-54.
36. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw. 2001;12(1):56-61. (Pubitemid 32281190)
37. Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther. 2012;35(6):714-22.
38. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31(2):53-9.
39. Blythe MJ, Flower DR. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci. 2005;14(1):246-8. (Pubitemid 40054138)
40. De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol. 2008;8(5):620-6.
41. Greenbaum JA, Andersen PH, Blythe M, Bui H-H, Cachau RE, Crowe J, et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit. 2007;20(2):75-82. (Pubitemid 46761248)
42. Giacò L, Amicosante M, Fraziano M, Gherardini PF, Ausiello G, Helmer-Citterich M, et al. B-Pred, a structure based B-cell epitopes prediction server. Adv Appl Bioinform Chem. 2012;5:11-21.
43. Giese C, Lubitz A, Demmler CD, Reuschel J, Bergner K, Marx U. Immunological substance testing on human lymphatic micro-organoids in vitro. J Biotechnol. 2010;148(1):38-45.
44. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002;3(4):349-60. (Pubitemid 35364009)
45. Katsutani N, Yoshitake S, Takeuchi H, Kelliher JC, Couch RC, Shionoya H. Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice. Fundam Appl Toxicol. 1992;19(4):555-62. (Pubitemid 23013126)
46. Bellomi F, Muto A, Palmieri G, Focaccetti C, Dianzani C, Mattei M, et al. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol. 2007;30(3):241-6. (Pubitemid 47264881)
47. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997;14(10):1472-8. (Pubitemid 27481082)
48. Hermeling S, Schellekens H, Maas C, Gebbink MFBG, Crommelin DJA, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95(5):1084-96. (Pubitemid 43723167)
49. Van Beers MMC, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res. 2011;28(10):2393-402.
50. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H, Filipe V. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs. 2012;5:4(6).
51. Van Beers MMC, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods. 2010;352(1-2):32-7.
52. Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994;37(12):1178-85. (Pubitemid 24356756)
53. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med. 1989;6(4):275-81. (Pubitemid 20108304)
54. Lee HJ, Riley G, Johnson O, Cleland JL, Kim N, Charnis M, et al. In vivo characterization of sustained-release formulations of human growth hormone. J Pharmacol Exp Ther. 1997;281(3):1431-9. (Pubitemid 27258404)
55. Zwickl CM, Cocke KS, Tamura RN, Holzhausen LM, Brophy GT, Bick PH, et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam Appl Toxicol. 1991;16(2):275-87.
56. Zwickl CM, Smith HW, Zimmermann JL, Wierda D. Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6-week period. Arzneimittelforschung. 1995;45(4):524-8.
57. Center for Biologics Evaluation and Research. Meeting of the biological response modifiers advisory committe. July 15, Bethesda MD. Food and Drug Administration. 1999.
58. Gunn H. Immunogenicity of recombinant human interleukin-3. Clin Immunol Immunopathol. 1997;83(1):5-7. (Pubitemid 27128385)
59. Black KE, Murray JA, David CS. HLA-DQ determines the response to exogenous wheat proteins: a model of gluten sensitivity in transgenic knockout mice. J Immunol. 2002;169(10):5595-600. (Pubitemid 35291659)
60. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997;185(6):1113-22. (Pubitemid 27136803)
61. Madoiwa S, Yamauchi T, Hakamata Y, Kobayashi E, Arai M, Sugo T, et al. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost. 2004;2(5):754-62. (Pubitemid 40185714)
62. Madoiwa S, Yamauchi T, Kobayashi E, Hakamata Y, Dokai M, Makino N, et al. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A. J Thromb Haemost. 2009;7(5):811-24.
63. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. 1996;14(7):845-51. (Pubitemid 26239182)
64. Geluk A, Taneja V, van Meijgaarden KE, Zanelli E, Abou-Zeid C, Thole JE, et al. Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc Natl Acad Sci U S A. 1998;95(18):10797-802. (Pubitemid 28413148)
65. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997;15(2):146-56. (Pubitemid 27061633)
66. Neeno T, Krco CJ, Harders J, Baisch J, Cheng S, David CS. HLA-DQ8 transgenic mice lacking endogenous class II molecules respond to house dust allergens: identification of antigenic epitopes. J Immunol. 1996;156(9):3191-5. (Pubitemid 26123532)
67. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood. 2005;106(5):1565-73. (Pubitemid 41208567)
68. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J-C, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304(5667):104-7. (Pubitemid 38451466)
69. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301-16.
70. Getts DR, Getts MT, McCarthy DP, Chastain EML, Miller SD. Have we overestimated the benefit of human(ized) antibodies? MAbs. 2010;2(6):682-94.
71. Scott DW, De Groot AS. Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis. 2010;69 Suppl 1:72-6.
72. Watanabe Y, Takahashi T, Okajima A, Shiokawa M, Ishii N, Katano I, et al. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol. 2009;21(7):843-58.
73. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12(11):786-98.